German rebate exemptions under threat
This article was originally published in Scrip
Executive Summary
Exemptions for struggling pharma companies from the obligatory rebates that all firms must offer German health insurers are under scrutiny from the European Commission. The commission has opened an investigation into the opt-outs, claiming they could be in breach of EU guidelines on state aid for rescuing and restructuring companies in financial difficulties.